<DOC>
	<DOCNO>NCT01254838</DOCNO>
	<brief_summary>The purpose study evaluate safety CTL reaction novel peptide vaccination advance renal cell carcinoma</brief_summary>
	<brief_title>Novel Peptide Vaccination Patients With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>DISEASE CHARACTERISTICS advance renal cell carcinoma already show resistance standard treatment PATIENTS CHARACTERISTICS 1 . Patients show resistance hormonal therapy chemotherapy 2 . Histological diagnosis adenocarcinoma 3 . HLAA*0201/0206 4 . ECOG performance status 0 2 5 . Age ≥ 20 year , ≤80 year 6 . WBC≥ 2,000/mm³ , ≤12000/mm³ hemoglobin≥ 8.0g/dl Platelet count ≥ 70000/mm³ AST , ALT ≤100 IU/l Total bilirubin ≤ 1.5 mg/dl Creatinine ≤ 1.0 mg/dl PaO2≥ 70mmHg 7. life expectancy ≥ 3months 8 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeding 3 . Patients willing childbearing ( Refusal inability use effective mean contraception ) 4 . Serious infection require antibiotic 5 . Concomitant treatment steroid immunosuppressing agent 6 . Other malignancy difficult control . 7 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>